


PI3K/Akt/mTOR-IN-4

Cat. No.:	HY-163511
Molecular Formula:	C ₂₉ H ₂₉ FN ₄ O ₃
Molecular Weight:	500.56
Target:	Akt; Apoptosis; mTOR; PI3K; Microtubule/Tubulin
Pathway:	PI3K/Akt/mTOR; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent PI3K/Akt/mTOR and tubulin polymerization inhibitor. PI3K/Akt/mTOR-IN-4 induce apoptosis and cell cycle arrest at G2/M phase. PI3K/Akt/mTOR-IN-4 decreases the expression of p-PI3K, p-Akt, and p-mTOR, β -tubulin ^[1] .																		
In Vitro	<p>PI3K/Akt/mTOR-IN-4 (compound 4r) (0-100 μM; 48 h) shows antiproliferative activity with IC₅₀s of 3.38, 5.03, 7.24, 21.08, 23.96 μM for SiHa, HeLa, Ca Ski, LO2, HEK-293t cells, respectively^[1].</p> <p>PI3K/Akt/mTOR-IN-4 (0-16 μM; 24 h) induces apoptosis and cell cycle arrest at G2/M phase^[1].</p> <p>PI3K/Akt/mTOR-IN-4 (4, 8, 16 μM; 24 h) decreases the expression of phosphorylation of PI3K, Akt, mTOR level and β-tubulin protein in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SiHa, HeLa, Ca Ski, LO2, HEK-293t cells</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell proliferative with IC₅₀s of 3.38, 5.03, 7.24, 21.08, 23.96 μM for SiHa, HeLa, Ca Ski, LO2, HEK-293t cells, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SiHa cells</td> </tr> <tr> <td>Concentration:</td> <td>0-16 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Induced cell cycle arrest at G2/M phase with G2/M phase cells accumulating from 5.24 % (Ctrl) to 28.37 % (16 μM).</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SiHa cells</td> </tr> </table>	Cell Line:	SiHa, HeLa, Ca Ski, LO2, HEK-293t cells	Concentration:	0-100 μ M	Incubation Time:	48 h	Result:	Inhibited cell proliferative with IC ₅₀ s of 3.38, 5.03, 7.24, 21.08, 23.96 μ M for SiHa, HeLa, Ca Ski, LO2, HEK-293t cells, respectively.	Cell Line:	SiHa cells	Concentration:	0-16 μ M	Incubation Time:	24 h	Result:	Induced cell cycle arrest at G2/M phase with G2/M phase cells accumulating from 5.24 % (Ctrl) to 28.37 % (16 μ M).	Cell Line:	SiHa cells
Cell Line:	SiHa, HeLa, Ca Ski, LO2, HEK-293t cells																		
Concentration:	0-100 μ M																		
Incubation Time:	48 h																		
Result:	Inhibited cell proliferative with IC ₅₀ s of 3.38, 5.03, 7.24, 21.08, 23.96 μ M for SiHa, HeLa, Ca Ski, LO2, HEK-293t cells, respectively.																		
Cell Line:	SiHa cells																		
Concentration:	0-16 μ M																		
Incubation Time:	24 h																		
Result:	Induced cell cycle arrest at G2/M phase with G2/M phase cells accumulating from 5.24 % (Ctrl) to 28.37 % (16 μ M).																		
Cell Line:	SiHa cells																		

	Concentration:	0-16 μ M
	Incubation Time:	24 h
	Result:	Induced apoptosis the percentage of apoptotic cells were increased from 11.62 % (Ctrl) to 98.56 % (16 μ M).
	Western Blot Analysis ^[1]	
	Cell Line:	SiHa cells
	Concentration:	4, 8, 16 μ M
	Incubation Time:	24 h
	Result:	Decreased the expression of phosphorylation of PI3K, Akt, and mTOR, β -tubulin in a dose-dependent manner.
In Vivo	PI3K/Akt/mTOR-IN-4 (0-400 μ M; 0-96 h) shows no toxicity for zebrafish embryos ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	zebrafish embryos ^[1]
	Dosage:	0, 12.5, 25, 50, 100, 200, 400 μ M
	Administration:	0-96 h
	Result:	Showed no toxicity for zebrafish embryos.

REFERENCES

[1]. Li SS, et al. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition. Eur J Med Chem. 2024 Apr 16;271:116425.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA